Kathryn’s recent experience includes serving on Weil teams representing Illumina in winning a November 2021 jury verdict of willful infringement against BGI in a competitor patent dispute regarding DNA sequencing technologies and AbbVie in pending Hatch-Waxman litigation against Sandoz regarding method of treatment patents for one of its blockbuster drug products, Combigan.
Kathryn previously worked as a research scientist at a medical diagnostics company. She received her J.D. from New York University School of Law and her B.S. in chemistry from the University of Missouri–Columbia.